A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma Meeting Abstract


Authors: Shah, M. A.; Ilson, D.; Ramanathan, R. K.; Levner, A.; D'adamo, D.; Schwartz, L.; Casper, E.; Schwartz, G. K.; Kelsen, D. P.
Abstract Title: A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Meeting Title: 41st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 23
Issue: 16 Suppl.
Meeting Dates: 2005 May 13-17
Meeting Location: Orlando, FL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2005-06-01
Start Page: 314S
Language: English
ACCESSION: WOS:000230326602075
PROVIDER: wos
Notes: --- - Meeting Abstract: 4025 - 41st Annual Meeting of the American-Society-of-Clinical-Oncology - MAY 13-17, 2005 - Orlando, FL - "Source: Wos"
MSK Authors
  1. Gary Schwartz
    358 Schwartz
  2. David R D'Adamo
    37 D'Adamo
  3. Lawrence H Schwartz
    281 Schwartz
  4. Manish Shah
    174 Shah
  5. David H Ilson
    269 Ilson
  6. David P Kelsen
    332 Kelsen
  7. Ephraim S Casper
    57 Casper